DBVT
HEALTHCAREDBV Technologies
AI Insight
What's Moving DBVT Today?
No stock-specific AI insight has been generated for DBVT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.51$26.18
$16.11
Fundamentals
Market Cap$929M
P/E Ratio—
EPS$-4.50
Dividend Yield—
Dividend / Share—
ROE-158.9%
Profit Margin—
Debt / Equity—
Trading
Volume377K
Avg Volume (10D)—
Shares Outstanding59.2M
DBVT News
27 articles- DBV Technologies Announces Inclusion in the Euronext Tech Leaders IndexYahoo Finance·Jun 23, 2026
- European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday TradingYahoo Finance·Jun 23, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Monday TradingYahoo Finance·Jun 22, 2026
- DBV Technologies (ENXTPA:DBV) Advances Peanut Patch With New Phase 3 Data And Infant TrialYahoo Finance·Jun 17, 2026
- European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday TradingYahoo Finance·Jun 16, 2026
- DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?Yahoo Finance·Jun 15, 2026
- European Equities Traded in the US as American Depositary Receipts Increase in Friday Trading; Rise for WeekYahoo Finance·Jun 12, 2026
- DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 9, 2026
- DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026Yahoo Finance·Jun 8, 2026
- DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceYahoo Finance·Jun 5, 2026
- European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Rise for WeekYahoo Finance·Jun 5, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingYahoo Finance·Jun 4, 2026
- Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 31, 2026Yahoo Finance·Jun 3, 2026
- DBV Technologies Announces the Results of its 2026 Combined General MeetingYahoo Finance·Jun 3, 2026
- DBV Technologies annonce le screening du premier participant de l’étude clinique de phase 2 THRIVE pour le patch VIASKIN® Peanut chez les nourrissons âgés de 6 à 12 mois allergiques à l’arachideGlobeNewswire Inc.·Jun 2, 2026
- DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut AllergyGlobeNewswire Inc.·Jun 2, 2026
- European Equities Traded in the US as American Depositary Receipts Rise in Tuesday TradingYahoo Finance·Jun 2, 2026
- DBV Technologies Stock Rebounds 2% After Prolonged DeclineIdéal Investisseur·May 22, 2026
- European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday TradingYahoo Finance·May 21, 2026
- European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday TradingYahoo Finance·May 18, 2026
- DBV Technologies Shares at €3.44: Up 77% Over the Year, Heading to the June 3rd General MeetingIdéal Investisseur·May 14, 2026
- Combined General Meeting of June 3, 2026Yahoo Finance·May 13, 2026
- European Equities Traded in the US as American Depositary Receipts Flat in Wednesday TradingYahoo Finance·May 13, 2026
- Adage insiders report 22,272,884 shares in DBV Technologies (NASDAQ: DBVT)Stock Titan·May 13, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 mars 2026GlobeNewswire Inc.·Apr 2, 2026
- Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026GlobeNewswire Inc.·Apr 2, 2026
All 27 articles loaded
Price Data
Open$15.69
Previous Close$16.11
Day High$16.58
Day Low$15.69
52 Week High$26.18
52 Week Low$8.51
52-Week Range
$8.51$26.18
$16.11
Fundamentals
Market Cap$929M
P/E Ratio—
EPS$-4.50
Dividend Yield—
Dividend / Share—
ROE-158.9%
Profit Margin—
Debt / Equity—
Trading
Volume377K
Avg Volume (10D)—
Shares Outstanding59.2M
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—